Psoriasis

"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

Descriptor ID	D011565
MeSH Number(s)	C17.800.859.675
Concept/Terms	Psoriasis Psoriasis Psoriases Pustulosis of Palms and Soles Pustulosis of Palms and Soles Pustulosis Palmaris et Plantaris Palmoplantaris Pustulosis Pustular Psoriasis of Palms and Soles

Below are MeSH descriptors whose meaning is more general than "Psoriasis".

Diseases [C]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Skin Diseases, Papulosquamous [C17.800.859]
Psoriasis [C17.800.859.675]

Below are MeSH descriptors whose meaning is related to "Psoriasis".

Below are MeSH descriptors whose meaning is more specific than "Psoriasis".

Psoriasis
Arthritis, Psoriatic

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.

Bar chart showing 45 publications over 22 distinct years, with a maximum of 6 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	1	0	1
2000	2	0	2
2002	1	1	2
2004	1	0	1
2005	1	0	1
2007	1	0	1
2008	3	0	3
2010	1	0	1
2012	1	1	2
2013	3	0	3
2014	1	0	1
2015	1	3	4
2016	1	1	2
2017	1	0	1
2018	1	2	3
2019	1	0	1
2020	6	0	6
2022	4	0	4
2023	1	0	1
2024	3	0	3
2025	1	0	1

Below are the most recent publications written about "Psoriasis" by people in Profiles.

Lebwohl M, Gooderham MJ, Warren RB, Tha?i D, Foley P, Gottlieb AB, Torres T, Popmihajlov Z, Jou YM, Linaberry M, Daamen C, Griffiths CEM. Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clin Exp Dermatol. 2025 Sep 25; 50(10):2030-2036.

View in: PubMed
Surve D, Fish A, Debnath M, Pinjari A, Lorenzana A, Piya S, Peyton S, Kulkarni A. Sprayable inflammasome-inhibiting lipid nanorods in a polymeric scaffold for psoriasis therapy. Nat Commun. 2024 10 19; 15(1):9035.

View in: PubMed
Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Tha?i D. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Aug; 38(8):1543-1554.

View in: PubMed
Jung SY, Han K, Jung JH, Park H, Shin DW. Cumulative exposure to metabolic syndrome affects the risk of psoriasis differently according to age group: a nationwide cohort study in South Korea. Br J Dermatol. 2024 02 16; 190(3):447-449.

View in: PubMed
Burden AD, Bissonnette R, Anatchkova M, Budhiarso I, Skalicky AM, Liberato ACS, Hu N, Thoma C, Gloede T, Kohlmann T, Lebwohl MG. Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2024 Jul; 38(7):1383-1390.

View in: PubMed
Nicolas SE, Bear MD, Kanaan AO, Coman OA, Dima L. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. Am J Ther. 2023 Nov-Dec 01; 30(6):e535-e542.

View in: PubMed
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley RG, Warren RB, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023 05 24; 188(6):749-759.

View in: PubMed
Burden AD, Bissonnette R, Lebwohl MG, Gloede T, Anatchkova M, Budhiarso I, Hu N, Thoma C, Skalicky AM, Bachelez H. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). J Eur Acad Dermatol Venereol. 2023 Jul; 37(7):1327-1335.

View in: PubMed
Whitley SK, Li M, Kashem SW, Hirai T, Igy?rt? BZ, Knizner K, Ho J, Ferris LK, Weaver CT, Cua DJ, McGeachy MJ, Kaplan DH. Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells. Sci Immunol. 2022 11 18; 7(77):eabq3254.

View in: PubMed
Levin NA, Rashighi M. Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence. Br J Dermatol. 2022 11; 187(5):631-632.

View in: PubMed

People

Explore

Similar Concepts

Top Journals